Guhan Pharmaceutical Group Co., Ltd. (SHE:000590)
China · Delayed Price · Currency is CNY 11.16
+0.06 (0.54%)
Apr 30, 2026, 3:04 PM CST
SHE:000590 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 336.95 | 330.5 | 337.61 | 398.53 | 346.53 | 297.28 |
Other Revenue | 7.17 | 7.17 | 5.6 | 6.12 | 4 | 3.49 |
| 344.12 | 337.67 | 343.21 | 404.65 | 350.53 | 300.77 | |
Revenue Growth (YoY) | 3.86% | -1.61% | -15.18% | 15.44% | 16.54% | 9.34% |
Cost of Revenue | 195.16 | 188.45 | 183.33 | 193.41 | 172.22 | 134.68 |
Gross Profit | 148.96 | 149.22 | 159.87 | 211.24 | 178.31 | 166.09 |
Selling, General & Admin | 145.32 | 154.09 | 165 | 176.63 | 145.98 | 125.73 |
Research & Development | 14.18 | 13.91 | 13.17 | 12.82 | 13.1 | 8.29 |
Other Operating Expenses | 7.2 | 7.02 | 7.15 | 7.73 | 8.05 | 6.95 |
Operating Expenses | 166.52 | 174.85 | 185.58 | 196.94 | 166.18 | 140.22 |
Operating Income | -17.56 | -25.63 | -25.7 | 14.3 | 12.13 | 25.87 |
Interest Expense | -3.39 | -3.39 | -3.66 | -4.46 | -1.15 | -0.47 |
Interest & Investment Income | 1.25 | 1.41 | 1.64 | 3.13 | 6.1 | 7.53 |
Other Non Operating Income (Expenses) | -5.87 | -6.24 | -26.72 | -8.08 | 1.34 | 1.76 |
EBT Excluding Unusual Items | -25.57 | -33.85 | -54.44 | 4.88 | 18.42 | 34.68 |
Impairment of Goodwill | -13.2 | -13.2 | -118.44 | -5.5 | - | - |
Gain (Loss) on Sale of Investments | - | - | -0.87 | 1.9 | 0.11 | 0.15 |
Gain (Loss) on Sale of Assets | 2.3 | 2.42 | 0 | 13.33 | 0.02 | 0.51 |
Asset Writedown | -11.36 | -11.72 | -0.27 | -0.09 | -0.67 | -1.99 |
Other Unusual Items | 6.76 | 6.76 | 51.87 | 15.16 | 4 | 8.49 |
Pretax Income | -41.08 | -49.59 | -122.14 | 29.68 | 21.88 | 41.84 |
Income Tax Expense | -0.45 | 0.49 | 5.09 | 4.79 | 3.74 | 6.4 |
Earnings From Continuing Operations | -40.62 | -50.07 | -127.23 | 24.89 | 18.14 | 35.44 |
Net Income to Company | -40.62 | -50.07 | -127.23 | 24.89 | 18.14 | 35.44 |
Minority Interest in Earnings | -0.45 | -0.44 | 1.76 | 0.36 | -0.03 | 0 |
Net Income | -41.07 | -50.52 | -125.47 | 25.25 | 18.11 | 35.44 |
Net Income to Common | -41.07 | -50.52 | -125.47 | 25.25 | 18.11 | 35.44 |
Net Income Growth | - | - | - | 39.41% | -48.90% | 55.96% |
Shares Outstanding (Basic) | 239 | 239 | 239 | 239 | 239 | 239 |
Shares Outstanding (Diluted) | 239 | 239 | 239 | 239 | 239 | 239 |
Shares Change (YoY) | -0.03% | - | - | - | - | - |
EPS (Basic) | -0.17 | -0.21 | -0.52 | 0.11 | 0.08 | 0.15 |
EPS (Diluted) | -0.17 | -0.21 | -0.52 | 0.11 | 0.08 | 0.15 |
EPS Growth | - | - | - | 39.42% | -48.91% | 55.96% |
Free Cash Flow | 8.45 | -19.85 | -14.71 | -51.43 | 35.79 | -0.68 |
Free Cash Flow Per Share | 0.04 | -0.08 | -0.06 | -0.21 | 0.15 | -0.00 |
Gross Margin | 43.29% | 44.19% | 46.58% | 52.20% | 50.87% | 55.22% |
Operating Margin | -5.10% | -7.59% | -7.49% | 3.53% | 3.46% | 8.60% |
Profit Margin | -11.94% | -14.96% | -36.56% | 6.24% | 5.17% | 11.78% |
Free Cash Flow Margin | 2.46% | -5.88% | -4.29% | -12.71% | 10.21% | -0.23% |
EBITDA | 11.8 | 3.13 | 0.62 | 39.51 | 33.54 | 42.59 |
EBITDA Margin | 3.43% | 0.93% | 0.18% | 9.76% | 9.57% | 14.16% |
D&A For EBITDA | 29.36 | 28.75 | 26.33 | 25.21 | 21.41 | 16.72 |
EBIT | -17.56 | -25.63 | -25.7 | 14.3 | 12.13 | 25.87 |
EBIT Margin | -5.10% | -7.59% | -7.49% | 3.53% | 3.46% | 8.60% |
Effective Tax Rate | - | - | - | 16.14% | 17.09% | 15.29% |
Revenue as Reported | 337.67 | 337.67 | 343.21 | 404.65 | 350.53 | 300.77 |
Advertising Expenses | - | 25.63 | 30 | 42.8 | 27.44 | 10.13 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.